Anthony, S. J., J. H. Epstein, K. A. Murray, I. Navarrete-Macias, C. M. Zambrana-Torrelio, A. Solovyov, R. Ojeda-Flores, N. C. Arrigo, A. Islam, S. Ali Khan, P. Hosseini, T. L. Bogich, K. J. Olival, M. D. Sanchez-Leon, W. B. Karesh, T. Goldstein, S. P. Luby, S. S. Morse, J. A. Mazet, P. Daszak, and W. I. Lipkin. 2013. A strategy to estimate unknown viral diversity in mammals. MBio 4(5):e00598-e00613.
Butler, D. 2015. How to beat the next Ebola. Nature (524):22-25.
Gates, B. 2015. The next epidemic: Lessons from Ebola. New England Journal of Medicine 372:1381-1384.
Ge, X. Y., J. L. Lin, X. L. Yang, A. A. Chmura, G. Zhu, J. H. Epstein, et al. 2013. Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature (503):535–538. http://dx.doi.org/10.1038/nature12711.
Gire, S. K., A. Goba, K. G. Andersen, R. S. Sealfon, D. J. Park, L. Kanneh, S. Jalloh, M. Momoh, M. Fullah, G. Dudas, S. Wohl, L. M. Moses, N. L. Yozwiak, S. Winnicki, S. B. Matranga, C. M. Malboeuf, J. Qu, A. D. Gladden, S. F. Schaffner, X. Yang, P. P. Jiang, M. Nekoui, A. Colubri, M. R. Coomber, M. Fonnie, A. Moigboi, M. Gbakie, F. K. Kamara, V. Tucker, E. Konuwa, S. Saffa, J. Sellu, A. A. Jalloh, A. Kovoma, J. Koninga, I. Mustapha, K. Kargbo, M. Foday, M. Yillah, F. Kanneh, W. Robert, J. L. Massally, S. B. Chapman, J. Bochicchio, C. Murphy, C. Nusbaum, S. Young, B. W. Birren, D. S. Grant, J. S. Scheiffelin, E. S. Lander, C. Happi, S. M. Gevao, A. Gnirke, A. Rambaut, R. F. Garry, S. H. Khan, and P. C. Sabeti. 2014. Genomic surveillance elucidates Ebola virus origin and transmission during the 2014 outbreak. Science 345(6202):1369-1372.
Jones, K. E., N. G. Patel, M. A. Levy, A. Storeygard, D. Balk, J. L. Gittleman, and P. Daszak. 2008. Global trends in emerging infectious diseases. Nature 451(7181):990-993.
Kinch, M. S., E. Patridge, M. Plummer, and D. Hoyer. 2014. An analysis of FDA-approved drugs for infectious disease: Antibacterial agents. Drug Discovery Today 19(9):1283-1287.
Li, W., Z. Shi, M. Yu, W. Ren, C. Smith, J. H. Epstein, H. Wang, G. Crameri, Z. Hu, H. Zhang, J. Zhang, J. McEachern, H. Field, P. Daszak, B. T. Eaton, S. Zhang, and L. F. Wang. 2005. Bats are natural reservoirs of SARS-like coronaviruses. Science 310(5748):676-679.
Matheny, J., M. Mair, A. Mulcahy, and B. T. Smith. 2007. Incentives for Biodefense Countermeasure Development. Biosecurity and Bioterrorism: Biodefense Strategy, Practice and Science 5:228-238.
Maurice, J. 2015. Too many unknowns stymie response to MERS. World Report. Lancet. http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(15)61186-2.pdf (accessed July 29, 2015).
Memish, Z. A., N. Mishra, K. J. Olival, S. F. Fagbo, V. Kapoor, J. H. Epstein, R. Alhakeem, A. Durosinloun, M. Al Asmari, A. Islam, A. Kapoor, T. Briese, P. Daszak, A. A. Al Rabeeah, and W. I. Lipkin. 2013. Middle East respiratory syndrome coronavirus in bats, Saudi Arabia. Emerging Infectious Diseases 19(11):1819-1823.
Nolan, T., S. Roy-Ghanta, M. Montellano, L. Weckx, R. Ulloa-Gutierrez, E. Lazcano-Ponce, A. Kerdpanich, M. A. Safadi, A. Cruz-Valdez, S. Litao, F. S. Lim, A. M. de Los Santos, M. A. Weber, J. C. Tinoco, M. H. Mezerville, I. Faingezicht, P. Kosuwon, P. Lopez, C. Borja-Tabora, P. Li, S. Durviaux, L. Fries, G. Dubin, T. Breuer, B. L. Innis, and D. W. Vaughn. 2014. Relative efficacy of AS03-adjuvanted pandemic influenza A(H1N1) vaccine in children: results of a controlled, randomized efficacy trial. Journal of Infectious Diseases 210(4):545-557.
Osterholm, M. T., N. S. Kelley, A. Sommer, and E. A. Belongia. 2012. Efficacy and effectiveness of influenza vaccines: A systematic review and meta-analysis. Lancet Infectious Diseases 12(1):36-44.
PCAST (President’s Council of Advisors on Science and Technology). 2010. Report to the president on reengineering the influenza vaccine production enterprise to meet the challenges of pandemic influenza. https://www.whitehouse.gov/sites/default/files/microsites/ostp/PCAST-Influenza-Vaccinology-Report.pdf (accessed June 30, 2015).
Porter, M. E., and M. R. Kramer. 2011. Creating Shared Value. Harvard Business Review January-February issue. https://hbr.org/2011/01/the-big-idea-creating-shared-value (accessed June 30, 2015).
Schieffelin, J. S., J. G. Shaffer, A. Goba, M. Gbakie, S. K. Gire, A. Colubri, R. S. Sealfon, L. Kanneh, A. Moigboi, M. Momoh, M. Fullah, L. M. Moses, B. L. Brown, K. G. Andersen, S. Winnicki, S. F. Schaffner, D. J. Park, N. L. Yozwiak, P. P. Jiang, D. Kargbo, S. Jalloh, M. Fonnie, V. Sinnah, I. French, A. Kovoma, F. K. Kamara, V. Tucker, E. Konuwa, J. Sellu, I. Mustapha, M. Foday, M. Yillah, F. Kanneh, S. Saffa, J. L. Massally, M. L. Boisen, L. M. Branco, M. A. Vandi, D. S. Grant, C. Happi, S. M. Gevao, T. E. Fletcher, R. A. Fowler,
D. G. Bausch, P. C. Sabeti, S. H. Khan, and R. F. Garry; KGH Lassa Fever Program; Viral Hemorrhagic Fever Consortium; WHO Clinical Response Team. 2014. Clinical illness and outcomes in patients with Ebola in Sierra Leone. New England Journal of Medicine 371(22):2092-2100.
Sertkaya, A., J. Eyraud, A. Birkenbach, C. Franz, N. Ackerley, V. Overton, and K. Outterson. 2014. Analytical framework for examining the value of antibacterial products. http://aspe.hhs.gov/sp/reports/2014/antibacterials/rpt_antibacterials.cfm (accessed June 30, 2015).
Sharma, P., and A. Towse. 2011. New drugs to tackle antimicrobial resistance: Analysis of EU policy options. https://www.ohe.org/publications/new-drugs-tackle-antimicrobial-resistance-analysis-eu-policy-options (accessed June 30, 2015).
Spellberg, B., P. Sharma, and J. H. Rex. 2012. The critical impact of time discounting on economic incentives to overcome the antibiotic market failure. Nature Reviews Drug Discovery 11(2):168.
Trock, S. C., S. A. Burke, and N. J. Cox. 2012. Development of an influenza virologic risk assessment tool. Avian Diseases 56(4 Suppl):1058-1061.
